Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
5.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

562
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
562
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cobimetinib and Irinotecan Liposome.

Hospital pharmacy·2024
Same author

Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Breast Cancer.

Hospital pharmacy·2024
Same author

Drug Monographs: Trabectedin and Trifluridine-Tipiracil.

Hospital pharmacy·2024
Same author

Cancer Chemotherapy Update: Bevacizumab, Etoposide, and Cisplatin Regimen for Refractory Brain Metastases.

Hospital pharmacy·2017
Same author

Drug Monographs: Avelumab and Ribociclib.

Hospital pharmacy·2017
Same author

Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer.

Hospital pharmacy·2017

Related Experiment Video

Updated: Apr 1, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

Lenvatinib and Palbociclib.

Dominic A Solimando, J Aubrey Waddell

    Hospital Pharmacy
    |October 9, 2015
    PubMed
    Summary
    This summary is machine-generated.

    This review covers essential aspects of cancer chemotherapy for pharmacists, including complex regimens and toxic agents. It details the preparation, dispensing, and administration of antineoplastic therapies for malignant diseases.

    More Related Videos

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
    09:32

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

    Published on: October 17, 2025

    630
    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
    08:36

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

    Published on: April 7, 2023

    1.7K

    Related Experiment Videos

    Last Updated: Apr 1, 2026

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
    06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    2.4K
    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
    09:32

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

    Published on: October 17, 2025

    630
    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
    08:36

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

    Published on: April 7, 2023

    1.7K

    Area of Science:

    • Oncology Pharmacy
    • Chemotherapy Administration

    Background:

    • Cancer chemotherapy involves complex regimens and highly toxic agents.
    • Pharmacists require specialized knowledge for safe and effective patient care.

    Purpose of the Study:

    • To review key issues in the preparation, dispensing, and administration of antineoplastic therapy.
    • To discuss commercially available and investigational agents used in treating malignant diseases.

    Main Methods:

    • Literature review and expert commentary on current oncology pharmacy practices.
    • Discussion of challenges and best practices in managing antineoplastic agents.

    Main Results:

    • Highlights the critical role of pharmacists in managing complex chemotherapy protocols.
    • Addresses the safe handling and administration of cytotoxic and targeted therapies.

    Conclusions:

    • Emphasizes the need for continuous education for pharmacists in oncology.
    • Provides a resource for understanding antineoplastic agents and therapy management.